SANT中药单体组合通过调控自噬抑制HPSE高表达三阴性乳腺癌生长与血管生成
本研究基于益气活血解毒理论,将黄芪甲苷IV、α-茄碱、莲心碱和2,3,5,6-四甲基吡嗪组合为SANT,在体外和体内评价其抗HPSE相关三阴性乳腺癌作用。结果显示HPSE高表达与乳腺癌患者RFS(P=1.7e-12)和OS(P=0.00016)不良相关,SANT可抑制癌细胞增殖迁移、增强自噬流、抑制肿瘤生长与血管生成。
要点
- HPSE高表达与乳腺癌患者RFS和OS不良相关
- SANT体外抑制TNBC细胞增殖迁移并增强自噬流
- SANT体内抑制肿瘤生长和血管生成
核心结论
- SANT中药单体组合可能成为抗癌药物研发的有前景候选者,为利用天然化合物实现优化效果提供新策略。
研究设计与样本
- 研究利用数据库分析HPSE表达与乳腺癌患者生存的相关性,并采用MTS、Trans-well、划痕实验、共聚焦显微镜、Western blot及小鼠模型进行体外和体内评价。
- 体外评估SANT对细胞增殖和迁移的影响,体内通过肿瘤重量和体积或血清指标评价疗效与安全性。
- 对肿瘤组织进行人自噬PCR阵列和血管生成蛋白质组分析以探讨机制。
主要发现
- HPSE表达升高的患者RFS(P=1.7e-12)和OS(P=0.00016)均较差。
- SANT给药显著抑制癌细胞增殖和迁移,增强自噬流,并在体外轻微降低HPSE活性形式。
- SANT在体内抑制肿瘤生长和血管生成。
- 人自噬PCR阵列显示SANT增加ATG16L1、ATG9B、ATG4D基因表达,降低TMEM74和TNF基因表达。
- 血管生成蛋白质组分析显示SANT降低肿瘤中HB-EGF、thrombospondin-2、amphiregulin、leptin、IGFBP-9、EGF、凝血因子III和MMP-9(前体和活性形式)蛋白水平,升高serpin E1和血小板因子4蛋白表达。
临床怎么用
- SANT作为中药单体组合,在HPSE高表达的三阴性乳腺癌中显示出抑制肿瘤生长和血管生成的潜力,机制与调控自噬相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Astragalus mongholicus, Solanum nigrum Linn, Lotus plumule, Ligusticum are widely used traditional herbal medicines for cancer treatment in China. They were typical drugs selected from Gubenyiliu II and series of formula (GYII), which were developed on the foundation of YIQIHUOXUEJIEDU theory. In the present study, four active ingredients (Astragaloside IV, α-solanine, neferine, and 2,3,5,6-tetramethylpyrazine) derived from medicines above were applied in combination as SANT. AIM OF THE STUDY: Triple-negative breast cancer (TNBC) is a serious threat to women's health worldwide. Heparanase (HPSE) is often up-regulated in breast cancer with the properties of facilitating tumorigenesis and influencing the autophagy process in cancer cells. This study aimed at evaluating the anti-tumor potential of SANT in treating HPSE related TNBC both in-vitro and in-vivo. MATERIALS AND METHODS: In this study, we explored the correlation between HPSE expression and survival of breast cancer patients in databases. We performed MTS, trans-well and wound scratch assays to assess the impact of SANT on cell proliferation and migration. Confocal microscopy observation and western blots were applied to verify the autophagy flux induced by SANT. Mice models were employed to evaluate the efficacy and safety of SANT in-vivo by tumor weights and volumes or serum index, respectively. To analyze the underlying mechanisms of SANT, we conducted human autophagy PCR array and angiogenesis proteome profiler on tumor tissues. RESULTS: Patients with elevated HPSE expression were associated with a poor outcome in both RFS (P = 1.7e-12) and OS (P = 0.00016). SANT administration significantly inhibited cancer cells' proliferation and migration, enhanced autophagy flux, and slightly reduced the active form of HPSE in-vitro. SANT also suppressed tumor growth and angiogenesis in-vivo. Human autophagy PCR array results indicated that SANT increased the ATG16L1, ATG9B, ATG4D gene expressions while decreased TMEM74 and TNF gene expressions.Angiogenesis proteome profiler results showed SANT reduced protein level of HB-EGF, thrombospondin-2, amphiregulin, leptin, IGFBP-9, EGF, coagulation factor III, and MMP-9 (pro and active form) in tumor, raised the protein expression of serpin E1 and platelet factor 4. CONCLUSIONS: These findings indicated that herbal compounds SANT may be a promising candidate in anti-cancer drug discovery. It also provides novel strategies for using natural compounds to achieve optimized effect.
引用
- Li QW, Zhang GL, Hao CX, et al. SANT, a novel Chinese herbal monomer combination, decreasing tumor growth and angiogenesis via modulating autophagy in heparanase overexpressed triple-negative breast cancer. J Ethnopharmacol. 2020. PMID: 33011366. doi:10.1016/j.jep.2020.113430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。